Thanks to Audible and the new Audible Original Power Moves for supporting industry focus.

Power Moves by Adam Grant is available and you can get it for free.

When you sign up for a free audible trial at audible.com slash full power, that's all one word, or text full

power to 500, 500. the So, Welcome to Industry Focus, the show that dives into a different sector of the stock market every day.

Today is Wednesday, February the 13th, and we're talking health care. I'm your host Shannon Jones.

I'm joined via Skype by health care guru Todd Campbell. Todd, how are you?

It's been a crazy week, Shannon. I tell you, my son slipped in the snow. We've got lots of snow here in New Hampshire, which was rare. It hasn't been very snowy at all this winter. And sure enough, he slipped and broke his arm. So I've been running around the last 24 hours

Helping him get himself all settled in so it's been a little crazy

Been a little hectic in the Campbell household for sure certainly hope he feels better that's a terrible

thing to do I've slipped on the ice before

uh... thankfully didn't break anything although i felt like i broke my

my entire pelvis when i did but was okay so I understand how it feels but but

glad he is on the mend I'm even more excited for this week Todd because it's been

a bit since we've actually done like a good just news round up and

there has been really I guess no shortage of interesting news that has come out in

the health care space really excited to talk about the stories and headlines we've been seeing lately.

Today's show is going to be a great reminder to biotech investors that, you know, frustrating flops are pretty common and they can pose a very big risk so they should not be

underestimated. Yeah first up disappointing study results came out from biotech giant

Gilead Sciences that's ticker symbol G I L D this week, Todd, yet another black eye for a

company that's had a rough couple of years and has really been desperate for some

good news, especially drugs that could help drive growth, because they've been in need of growth for some time.

Before we get into the study data that they read out this week, Todd, all focus for Gilead has really been on a market called

...